173459-52-4

Basic information

• Product Name: 1H-INDAZOLE-1-CARBOXYLIC ACID,7-NITRO-,1,1-DIMETHYLETHYL ESTER
• Synonyms: 1H-INDAZOLE-1-CARBOXYLIC ACID,7-NITRO-,1,1-DIMETHYLETHYL ESTER;tert-butyl 7-nitro-1H-indazole-1-carboxylate
• CAS NO: 173459-52-4
• Molecular Formula: C₁₂H₁₃N₃O₄
• Molecular Weight: 263.252
• Mol File: 173459-52-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-INDAZOLE-1-CARBOXYLIC ACID,7-NITRO-,1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDAZOLE-1-CARBOXYLIC ACID,7-NITRO-,1,1-DIMETHYLETHYL ESTER(173459-52-4)
• EPA Substance Registry System: 1H-INDAZOLE-1-CARBOXYLIC ACID,7-NITRO-,1,1-DIMETHYLETHYL ESTER(173459-52-4)

Safety Data

• Hazardous Substances Data: 173459-52-4(Hazardous Substances Data)

Usage

Structure

1H-Indazole-1-carboxylic acid, 7-nitro, 1,1-dimethylethyl ester

Type of compound

Nitro derivative of indazole

Usage

Building block in organic synthesis, intermediate in the synthesis of pharmaceuticals and agrochemicals

Reactivity

Diverse reactivity, ability to introduce the indazole-1-carboxylic acid motif into various molecules

Hazardous

Yes, can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 1122-58-3 dmap 
• 34619-03-9 tert-butyldicarbonate 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 2942-42-9 7-Nitroindazole 

Downstream Products

• 173459-53-5 7-amino-1-tert-butoxycarbonyl-indazole 
• 2942-42-9 7-Nitroindazole 

Relevant articles and documents

METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS

A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), STR1 where R 1 is C 1-C 6 alkyl, C 3-6 cycloalkyl, phenyl, or substituted phenyl; R 2 is C 3-6 alkyl, C 3-6 cycloalkyl, C 3-6 alkenyl, benzyl, phenylC 1-3 alkyl or substituted phenyl; or NR 1 R 2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C 1-6 alkyl, C 1-6 alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0, 1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R 3, R 4, R 5 and R 8 are selected from a variety of substituents; X is nitrogen, nitroso or R 8 ; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).